Editas Medicine, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report; quarterly-specific financial results are not provided in the supplied text. Editas is a clinical-stage genome-editing company with no approved products or product-sales revenue.
Financial performance and position
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Collaboration and other R&D revenue | $78.1 million | $19.7 million | Increase mainly from the Vertex license; no product-sales revenue. |
| Research and development expense | $177.7 million | $175.0 million | Up 2%; lower external R&D spending was largely offset by higher sublicense and license fees. |
| General and administrative expense | $69.7 million | $70.7 million | Down 1%; higher professional services were offset by lower stock-based compensation. |
| Operating loss | $169.2 million | $226.0 million | Improved primarily with higher collaboration revenue. |
| Interest income, net | $17.6 million | $5.5 million | Higher invested balances and favorable interest rates. |
| Net loss | $153.2 million | $220.4 million | Loss per share was $2.02 versus $3.21. |
| Cash, cash equivalents and marketable securities | $427.1 million | $437.4 million | Down $10.2 million year over year. |
| Net cash used in operating activities | $132.2 million | $177.3 million | Operating cash use decreased. |
Gross or product margins are not meaningful because Editas has no product sales. At year-end, total assets were $499.2 million and total liabilities were $150.1 million. The filing does not report conventional borrowings; liabilities include operating lease obligations and deferred revenue. Operating lease liabilities totaled $36.5 million, with $14.8 million of minimum lease payments due in 2024. A separate manufacturing-space agreement provides for up to $85.4 million of payments over ten years once commenced.
Financing cash flow was $118.0 million, primarily from a June 2023 public offering that raised $117.1 million net and increased shares outstanding. Investing cash flow was a $3.7 million use, reflecting securities purchases and maturities broadly offsetting each other and $4.7 million of property and equipment purchases. Cash, cash equivalents and restricted cash decreased by $17.9 million.
Business developments and outlook
- Lead program: Reni-cel (formerly EDIT-301), an experimental ex vivo CRISPR/Cas12a medicine for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), is being studied in the RUBY and EdiTHAL trials. Through February 28, 2024, the company reported 40 patients enrolled and 18 dosed in RUBY, and nine enrolled and seven dosed in EdiTHAL.
- Early clinical findings: In data presented in December 2023, the company reported no post-infusion vaso-occlusive events among 11 RUBY patients at the reported cutoff; six patients with at least five months’ follow-up had normal total hemoglobin and fetal hemoglobin above 40%. In EdiTHAL, all six reported patients engrafted; five with more than one month of follow-up had total hemoglobin above the stated transfusion-independence threshold. Follow-up was limited, and these early findings do not establish efficacy or approval.
- Vertex license: Editas received a $50 million upfront payment and recognized $60 million of 2023 revenue, including the first annual license-fee installment. It may receive a further $50 million contingent payment and annual fees of $10 million to $40 million through 2034, subject to contract terms. Payments related to licensed Cas9 technology are subject to a mid-double-digit percentage payment to Broad and Harvard.
- Other collaborations: The Vor Bio agreement provides an upfront payment and potential milestones and royalties. The BMS collaboration covers engineered alpha-beta T-cell programs and has resulted in 13 programs; future milestone and royalty receipts are contingent.
- Pipeline and execution: Management targeted in vivo preclinical proof-of-concept for an undisclosed indication by year-end 2024 and expected further RUBY and EdiTHAL data updates in mid-2024 and by year-end 2024. The company also planned to move reni-cel cell processing to a new third-party facility in the first half of 2024.
- Runway: Management expected year-end 2023 cash, equivalents and securities, together with near-term Vertex annual fees and the contingent Vertex payment, to fund operating and capital requirements into 2026. This forecast depends on uncertain payments and spending assumptions. The financial statements separately state that existing resources were expected to cover at least 12 months from their February 28, 2024 issuance date.
Risks, contingencies and unusual items
- Editas has incurred substantial losses since inception, had a $1.23 billion accumulated deficit at year-end, expects further losses, and may need additional financing. Equity financing could dilute shareholders; collaboration or licensing financing could require surrendering rights.
- Reni-cel is the company’s only clinical-stage program and is central to its prospects. Trials remain early, and safety, durability, regulatory approval, manufacturing scale-up, reimbursement and commercialization are uncertain. The filing identifies off-target editing and other potential serious adverse events as risks.
- Competition has intensified: FDA approvals of Vertex’s CASGEVY and bluebird bio’s LYFGENIA for SCD create potential competitors if reni-cel is approved.
- CRISPR patent rights are subject to ongoing priority, validity and opposition disputes, including U.S. interference proceedings and European patent challenges. Editas also has significant licensor expense-reimbursement, milestone, royalty and potential market-capitalization success-payment obligations.
- Manufacturing capacity and dependence on third parties, high potential treatment costs and uncertain payer coverage, evolving genetic-medicine regulation, and changing drug-pricing rules could affect development and future commercial prospects.
- Revenue is concentrated in collaboration and license arrangements and may fluctuate with milestone, option and license events. Of BMS-related deferred revenue, $56.7 million was classified as long-term at year-end.
- The company reported no litigation contingency reserves at December 31, 2023. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also reported effective disclosure controls.
Important facts for investors to verify
- Review updated RUBY and EdiTHAL patient counts, follow-up duration, safety events, engraftment, hemoglobin outcomes and trial plans; distinguish preliminary data from longer-term evidence.
- Confirm whether the contingent $50 million Vertex payment is achieved and track actual annual license-fee receipts, related licensor payments and revenue recognition.
- Compare actual cash use and financing needs with management’s runway forecast into 2026, including the effect of the new manufacturing-space commitment.
- Monitor CRISPR patent proceedings, license terms and potential milestone, royalty and success-payment obligations.
- Assess reni-cel’s competitive position, manufacturing readiness and likely reimbursement against approved SCD therapies.
- Track share-count growth and potential dilution following the 2023 offering and any future financing.